Leadership Updates
BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, ...
Read More →
Dyno Therapeutics at Goldman Sachs Byte-ology Conference
Discussing the Convergence of Biotechnology and Technology Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman ...
Read More →
Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards
BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life ...
Read More →
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: ...
Read More →
The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A ...
Read More →
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Every day seems to bring a fundraising record and a new company launching in the biotech industry. Insider spoke with some of the smartest and ...
Read More →
Giant steps: Dyno closes $100M series A round for advanced capsid engineering
The allocation of capital to the build-out of next-generation gene therapies continues apace. Dyno Therapeutics Inc., a leader in applying artificial intelligence to advanced capsid ...
Read More →
Dyno raises $100 million to bring artificial intelligence to gene therapy
Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said Thursday that it has raised $100 million from investors.
Read More →
Dyno’s Eric Kelsic fills the tank in his quest for better AAV with a group of big-name supporters on board
Adeno-associated viruses (AAV) for gene therapy have received a ton of scrutiny throughout the field’s history after a smattering of safety scares and their limited ...
Read More →
Eric Kelsic recognized in Endpoints 20 under 40 list: The 20(+1) under 40 – Inside the next generation of biotech leaders
How does one decide who makes an “under 40” list? After the last nominations come in from staff and readers, we’re left to sort through ...
Read More →
AI Generates Unprecedented Diversity of AAV Capsids
Given their ability to transfer DNA into target cells, and non-pathogenic nature, adeno-associated viruses (AAVs)—the spherical protein structures enveloping the virus’ DNA genome—are the current ...
Read More →
Dyno sketches tens of thousands of viable next-gen AAV capsids with the help of machine learning — paper
Since its launch in May 2020, Dyno Therapeutics has touted its platform’s potential to discover viable variations of current-gen AAVs with noticeable limitations in terms ...
Read More →
Scientists turn to machine learning to tackle one of gene therapy’s biggest challenges
As the world charges to vaccinate the population against the coronavirus, gene therapy developers are locked in a counterintuitive race. Instead of training the immune ...
Read More →
Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies
Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss, was the first ...
Read More →
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Gene therapies are some of the hottest areas of investment in the biotech world, as are artificial-intelligence-assisted research methodologies, and “Dyno’s right there at the ...
Read More →
